Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| CXMT | GitLab | Pfizer | |
|---|---|---|---|
| Moat rating | none CXMT's 2026 interim report (published 2026-08-29) names scale and IDM technology as core competencies, but also concedes gaps. It says that compared with the leading international manufacturers the Company 'still has a certain gap in overall scale, technology accumulation and customer resources' (与国际头部厂商相比，公司在整体规模、技术积累、客户资源等方面仍然存在一定差距). It describes its scale effect as 'gradually emerging' (逐步显现), and its gross-margin risk covers the case where the scale effect cannot materialise over the long term (公司规模效应长期无法显现). Its excess returns span a single shortage. The retained-earnings note shows an accumulated deficit of ¥36.65bn entering 2026, after ¥1.87bn of 2025 net profit attributable to the parent, and the first-half 2025 net loss attributable to shareholders was ¥2.33bn. Then first-half 2026 revenue rose 873.64%, which the report attributes to the global DRAM supply shortage, higher prices and sharply higher volumes, and the main-business gross margin reached 84.84%. | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none On the report's own evidence, no candidate moat source qualifies. Cost scale: the report calls DRAM a highly standardised product (高度标准化的产品) in which the cost advantage of scale is a core competency. But CXMT ranks fourth globally by capacity, and the report, calculating on sales, puts Samsung, SK hynix and Micron at 33.96%, 34.48% and 23.41% of the 2025 global DRAM market, so the scale advantage lies with the leaders. IP: it reports 4,484 domestic patents (3,744 of them invention patents) and 3,400 overseas patents as of 2026-06-30. Yet it describes its core technology as reaching 'international advanced level' (国际先进水平) and flags possible IP disputes with competitors. Switching costs: ¥133.48bn of ¥150.31bn first-half 2026 revenue went through distributors, who under the report's revenue note decide their own resale prices. | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower TrendForce (2026-09-24) reports that CXMT's global DRAM revenue share rose to 9.5% in 2Q26 from 7.6% in 1Q26, 'placing it fourth behind Samsung at 39.4%, SK hynix at 24.9%, and Micron at 23.3%'. It is catching up through generation-skipping R&D. The interim report had its fifth process platform in customer certification, and a voluntary disclosure on 2026-09-21 announced that platform's mass production, adding that its products are not yet in scale sales and yields need time to ramp. TrendForce's listing analysis (2026-07-28) still says CXMT 'still trails Samsung, SK hynix, and Micron in advanced processes, product performance, yields, and certification by high-end customers'. | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak CXMT is a price taker riding the cycle. The interim report attributes first-half revenue growth to the global DRAM supply shortage, rising prices and sharply higher volumes. It records industry prices between 2015 and 2025 as high as $7.89/GB and as low as $1.78/GB in first-half 2023, and it states that the continued steep price rise is not sustainable. Main-business revenue was ¥15.22bn against cost of ¥13.29bn in first-half 2025, and ¥150.04bn against ¥22.75bn in first-half 2026. Most sales go through distributors, who set their own resale prices. | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | CXMT (ChangXin) is a Hefei-based IDM that designs and fabricates DDR5 and LPDDR4X/LPDDR5/5X/LPDDR6 memory and sells DRAM wafers, chips and modules. Its 2026 interim report says it reached its fourth process platform through a 'generation-skipping' (跳代研发) R&D strategy, and that it ranks first in China and fourth globally by shipments and sales. First-half 2026 revenue was ¥150.31bn (DDR series ¥69.47bn, LPDDR series ¥78.19bn), with a main-business gross margin of 84.84%. TrendForce puts its 2Q26 DRAM revenue share at 9.5%, up from 7.6% in 1Q26. The position is real but recent. The report concedes gaps to the three leaders in scale, technology and customers. The customers it names are Alibaba Cloud, ByteDance, Tencent, Lenovo, Xiaomi, Transsion, Honor, OPPO and vivo. On 2026-06-08 the US Defense Department added its subsidiary ChangXin Memory to the Section 1260H list. TrendForce notes that export controls leave CXMT relying on DUV multiple patterning rather than EUV, and that its prospectus 'has not disclosed a clear mass-production timetable' for HBM. The report itself warns that the continued steep rise in DRAM prices is not sustainable (价格的持续大幅上涨不具备可持续性) as international makers add capacity. | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream DRAM IDM selling wafers, chips and modules to server, smartphone, PC and automotive makers, mostly through distributors (¥133.48bn of ¥150.31bn first-half 2026 revenue). | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |